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Abstract 
Background: MEK inhibitors have gained large interest in oncology. Sensitivity to different 
cancer types, in particular melanoma, has been demonstrated. MEK inhibitors induce a 
transient retinopathy, which is considered a class effect. At present, only sparse data is 
available on retinal effects to long-term treatment with MEK inhibition. 
Patients and methods: Patients with advanced melanoma treated either with MEK inhibitor 
binimetinib alone or in combination with a BRAF inhibitor participated in different phase 1/2 
or phase 3 clinical trials underwent regular ophthalmological examinations including 
determination of visual function, biomicroscopy, dilated fundoscopy and optical coherence 
tomography (OCT). In this prospective, observational, study we collected ophthalmologic 
findings of these patients for a period of up to two years. The diagnosis of retinopathy was 
based on the presence of defined criteria in OCT. 
Results: Between Oct 1, 2011, and July 31, 2015, 62 patients were treated with MEK 
inhibitor binimetinib alone or in combination with a BRAF inhibitor. In 92% to 100% of the 
patients, binimetinib alone or in combination caused dose-dependent retinal lesions with 
serous neuroretinal detachments and oedema, especially during the first weeks of treatment. 
There was a strong dependency from the time interval after medication. With ongoing 
treatment, retinal volume and thickness decreased to levels below baseline. No functional 
deficits or structural changes on high resolution OCT scans even after a treatment period up to 
two years were found. 
Conclusions: Binimetinib induces a specific retinopathy with daily fluctuations depending on 
the time interval from medication intake. The retinopathy recovers over time, but may still be 
detectable after many months with subtle signs. Our measurements suggest a loss of retinal 
volume and thickness. No functional relevance was detected so far. 
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Key Message 
MEK inhibitor binimetinib induces a dose- and time-dependent retinopathy with mild visual 
symptoms and reversible functional deficits. Daily fluctuations of the lesions are strongly 
associated with the time interval from medication intake and make the time point of 
examination crucial. Altogether, binimetinib is safe with regard to ocular adverse effects for 
treatment durations of up to two years.  
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Introduction 
MEK inhibitors have gained large interest in oncology. They target a protein kinase involved 
in the Mitogen-Activated Protein Kinase (MAPK) pathway, which plays a relevant role in the 
development of various cancers [1]. Sensitivity to MEK inhibitors has been demonstrated as 
monotherapy or in combination in different cancer types. Moreover, tumour control in 
patients has been shown in clinical studies [2-7]. The introduction of novel treatment 
strategies such as targeted therapy and immunomodulation have prolonged patient survival in 
metastatic melanoma [8-11]. The addition of selective MEK inhibitors to the BRAF inhibitor 
treatment improved clinical outcome and delayed the development of drug resistance in 
BRAF mutated melanoma patients [12, 13]. Moreover, MEK inhibitors have demonstrated 
activity in NRAS mutated melanoma as well [2]. Common MEK inhibitor-related adverse 
events include acneiform skin rash, oedema, retinopathy and diarrhoea [14, 15]. Using 
combined therapy regimens many adverse events observed in BRAF monotherapy disappear 
or decrease in frequency. However, drug-related adverse events typical for MEK inhibitors, 
including retinal events, persist [8-10]. Some clinical features of MEK inhibitor-associated 
retinopathy, resembling to the well-known central serous chorioretinopathy [16], have been 
described in two studies with about 30 patients and in three small case series [15, 17-20]. At 
present, no long-term data is available. In this work, we investigated the ophthalmological 
effects of the selective MEK inhibitor binimetinib alone or in combination with other kinases 
including the BRAF inhibitor encorafenib over many months.  
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Patients and methods 
Study design and participants 
For this prospective, observational study, patients with advanced BRAF- and NRAS-mutant 
cutaneous melanoma were observed with focus on MEK inhibitor treatment-related ocular 
side effects during treatment with binimetinib alone or binimetinib in combination with RAF 
inhibitors for a period up to two years.  
Patients were recruited from seven clinical trials: phase 1/2 open-label studies with 
binimetinib as monotherapy (NCT01320085), binimetinib in combination with the pan-
inhibitor RAF265 (NCT01352273), binimetinib in combination with the selective BRAF 
inhibitor encorafenib (NCT01543698), binimetinib in combination with encorafenib and a 
third agent after progression (NCT02159066), or binimetinib added to treatment after relapse 
on encorafenib monotherapy (NCT01820364). Patients were also included from Phase 3 two- 
or three-arm randomized, prospective, open label studies: binimetinib monotherapy versus 
dacarbazine in patients with NRAS Q61 mutation positive melanoma (NCT01763164) or a 
combination of encorafenib plus binimetinib versus monotherapy with either encorafenib or 
vemurafenib (NCT01909453). 
Patients were treated at the Department of Dermatology, University Hospital of Zurich. They 
underwent regular ophthalmological examinations according to the respective study protocols. 
Patients with an increased risk of retinal vein thrombosis, a history of vascular occlusion or 
previous central serous chorioretinopathy (CSR) were excluded. We assigned the patients 
according to their treatment in the context of the above mentioned trials to the following 
groups: binimetinib monotreatment, combined treatment with RAF inhibitors, and selective 
BRAF inhibitor monotreatment (Table 1). Patients with any pre-existing eye condition were 
analysed separately and reported in a separate paragraph.  
All patients gave written informed consent and all aspects of the study were approved by the 
local Ethics Committee. 
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Procedures 
All patients underwent full ophthalmological examinations at regular intervals, in accordance 
with each trial protocol as described elsewhere [15]. Briefly, examinations included an 
ophthalmological history, a record of the time and the dose of medication, determination of 
best corrected visual acuity, static perimetry (patients in phase 1/2 studies), slit-lamp 
examination, applanation tonometry, dilated fundoscopy, and multimodal imaging, especially 
optical coherence tomography (OCT). At each visit at least an OCT volume scan positioned 
on the fovea with the same acquisition protocol and rescan technology was performed. 
Segmentation errors were manually corrected. Only scans with good quality from patients 
with stable fixation were included. Blue laser autofluorescence has been recorded in all 
patients after a treatment duration of one year, in case of altered visual acuity, or in the 
presence of symptoms.  
Outcomes 
Incidence and severity of ocular side effects during long-term treatment with binimetinib were 
evaluated with the assessment of ocular symptoms, changes in visual function, slit lamp, and 
retinal findings. In fundoscopy we defined the presence of retinopathy if localized lesions 
were visible or if the typical bright retinal reflexes were blunted. An OCT positive retinopathy 
was defined in the presence of serous exudations and/ or oedema of the outer retinal layers. 
Evaluation of all possible retinal adverse events were assessed according to the same criteria 
for each session with regard to the morphology of the lesions (localized, bullous or widely 
extended, flat serous neuroretinal detachments), the location (foveal, extrafoveal or both), the 
presence of oedema, and the detection of segmentation errors. Oedema of the outer layers was 
defined as an increase in central retinal thickness (> 10µm) compared to baseline values 
(Heyex eye explorer software Version 1.9.10.0; Viewing module 6.3.4.0; Heidelberg 
Engineering, Heidelberg, Germany) and the appearance of four clearly separated, strongly 
reflective bands of the outer retina. 
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Statistical analysis 
All statistical analyses were performed with R (R Development Core Team, 2015) using the 
“lme4”- and “lmerTest” packages [21, 22]. Linear mixed model analyses were used to assess 
influences on visual acuity, central retinal thickness and retinal volume. The dose of 
binimetinib, treatment with a RAF inhibitor, duration of treatment, and the time elapsed since 
medication were introduced as independent variables in the mixed model analysis. The 
subject variable was added as a random intercept to the model. Baseline values (before the 
start of treatment) were used as the reference category. If not otherwise indicated, figures 
show mean ± standard deviation. P-values < 0.05 were considered to be statistically 
significant. 
Results 
Between Oct 1, 2011, and July 31, 2015, 62 patients were enrolled and evaluated at regular 
intervals with median observation period of 170 days (IQR 115 – 280 days, including 
examinations after treatment stop). Of the 62 patients, 13 were treated with binimetinib 
monotherapy, 10 with selective BRAF inhibitor monotherapy, and 39 with combination 
therapy. Seventeen patients on binimetinib alone or in combination were examined after 
treatment stop. Details of the patient characteristics are given in Table 1. 
MEK inhibitor-associated retinopathy was found in 12 of 13 patients during binimetinib 
monotherapy (92%), and in all 39 patients undergoing combination therapy. Selective BRAF 
inhibitor monotreatment caused no retinal changes. The sensitivity of biomicroscopy was 
72.5% in detecting the typical lesions or evidence of oedema compared to OCT.  
Five of thirteen patients (38%) on binimetinib monotherapy and 27 of 39 patients (69%) on 
combination therapy reported symptoms, while in patients undergoing RAF inhibitor 
monotherapy, two of ten patients (20%) were symptomatic (Table 1). Visual disturbances 
occurred especially during the first four weeks of treatment. On resuming binimetinib therapy 
after a treatment break, similar symptoms were experienced but were less pronounced. The 
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presence of visual symptoms was highly predictive for the detection of a retinopathy in OCT 
measurements (odds ratio 2.0; 95% CI 1.4 to 2.6; p < 0.001). This is, however, to be 
considered under the fact that only 34 of 51 (67%) of the patients having an OCT-positive 
retinopathy indicated visual symptoms. 
With regard to visual function, a dose-dependent attenuation of visual acuity was found 
related to the time point of binimetinib intake (p < 0.001 and p = 0.007, Supplementary table 
S1). Though, no influence was observed with regard to the duration of binimetinib treatment 
(p=0.118). Binimetinib therefore transiently attenuates visual acuity after medication intake, 
but even a prolonged exposure had no long-term effect on visual acuity. With regard to the 
results from perimetry, no significant changes in response to treatment with binimetinib were 
detected (mean defect versus values at baseline, p=0.979). No abnormalities in Roth 28-Hue 
Colour tests were observed after treatment periods of 6 to 24 month (d 3 colour confusions 
per eye).  
In slit lamp examination, no evident pathologies were detected during treatment with 
binimetinib or a BRAF inhibitor, with the exception of two patients who had previously been 
treated with ipilimumab. In these two patients, bilateral signs of an earlier anterior uveitis 
with posterior synechiae were found at screening. A third patient had a relapsing uveitis 
anterior together with other manifestations of a sarcoidosis during the study treatment. The 
condition of these patients was well controlled with local treatment. Three patients had 
intermittently elevated intraocular pressure together with general oedema. 
In fundoscopy, multiple, mainly bilateral, bullous lesions, often a larger one over the fovea, 
but distributed also far beyond the vascular arcades were found in patients on binimetinib 
alone and in combination with RAF265. The greyish-yellow round or oval lesions of various 
sizes were easy to overlook. They were not very prominent on biomicroscopy either. On 
combined treatment with binimetinib and encorafenib, larger localised bullous lesions have 
been found. However, only reduced retinal reflections and slightly blurred optic nerve 
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margins as an evidence of retinal oedema remained after many months of treatment. These 
affected patients were extremely photosensitive for many months and did not tolerate 
fundoscopy.  
In contrast to fundoscopy, the examination with the scanning laser ophthalmoscope (SLO) 
was better accepted allowing questionable retinal lesions to be identified clearly. No 
abnormalities were found in blue laser autofluorescence. Enhanced depth imaging (EDI) of 
choroidal thickness during active retinopathy was within the normal age dependent limits.  
The lesions (bullae, cleft or oedema) in OCT were most often observed both foveal and 
extrafoveal (Figure 1A). The morphological appearance of the retinal lesions differed 
between binimetinib mono- and combined treatment (Table 1). Bullous lesions were more 
often visible on monotreatment. On combined treatment, the typical finding was a flat 
neuroretinal detachment which expanded over a large part of the posterior pole (Figure 1B). 
This flat neuroretinal detachment was not identifiable on fundoscopy and was seen in the 
OCT scan only. Especially patients with bullae or oedema in the OCT measurements reported 
on visual disturbances (odds ratios: 5.7 and 3.6, respectively; 95% confidence intervals: 3.1 to 
10.7 and 2.0 to 6.3, respectively; both p-values < 0.001), while a flat neuroretinal detachment 
was unlikely to provoke symptoms (p = 0.080). 
The findings in OCT depended on the time that had elapsed since drug administration. The 
maximal changes in the retina occurred within four hours after medication intake (Figure 2). 
Shortly before administration of the drug, the same patients showed in some cases oedema, 
but most often no evidence of pathology. 30 minutes after medication intake, subtle 
segmentation errors in the outer retinal layers (pigment epithelium, interdigitation zone), 
occasionally with incipient oedema, appeared as an early sign of the drug effect. In some 
cases, this irregularity affected only the retinal pigment epithelium (RPE) (Supplementary 
Figure S1). About 60 minutes after drug administration, a mainly central thickening of the 
outer retinal layers appeared; another 15 to 30 minutes later, the first signs of an exudate were 
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detectable (Figure 3). These morphological changes resolved in the reverse order some four 
to five hours later.  
Especially during the first weeks of treatment with binimetinib a dose-dependent increase of 
retinal volume, as well as an increase in central retinal thickness were observed (p-values < 
0.001, Supplementary Table S2-4). These changes resolved gradually over 3-6 months and 
reached values that were even lower than at baseline within a year (Figure 4, Supplementary 
Figure S2). No influence of selective BRAF inhibitors on retinal parameters was found 
(Supplementary Table S2-4). On binimetinib monotherapy, 9 of 13 patients had to switch on 
intermittent treatment due to not eye-related adverse events. After each re-initiation, they 
experienced a relapse of a mild exudative retinopathy. All these patients on combined 
treatment continued over more than 6-12 months to develop flat neuroretinal detachments of 
variable amount or just only oedema during a short time window in response to medication.  
In a separate analysis, 17 of the 62 patients were examined after the end of treatment with 
regard to potential retinal residues of binimetinib-induced retinopathy. All were symptom-free 
and visual function tests were unchanged from baseline. We found no signs of degeneration 
such as changes in pigmentation in fundoscopy or in autofluorescence. As reported during 
active treatment with binimetinib, a reduction in retinal volume and thickness below pre-
treatment values was measured (Figure 4, Figure S2). This thinning of the retina persisted for 
at least a week after the end of treatment. The follow-up of surviving patients suggested a 
potential recovery. No irregularities in retinal architecture on OCT high resolution scans with 
a special attention to ellipsoid zone and outer nuclear layer were detected. 
Seven patients with pre-existing eye disease were analysed separately. Pre-existing conditions 
included: unilateral or bilateral macular oedema with epiretinal gliosis (n=3), extensive drusen 
within a dry age-related retinopathy and glaucomatous optic atrophy with well-controlled 
intraocular pressure (n=1), traumatic optic atrophy (n=1), only one functional eye and extreme 
myopia (n=1), severe panuveitis following ipilimumab (n=1). All patients had the typical 
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serous neuroretinal detachments, which were well documented with OCT and proceeded a 
similar course to those seen in the other study participants (Figure 5). Groups of drusen often 
encouraged serous detachments, which then required a little longer to resolve.  
 
Discussion 
In the present article we describe for the first time ophthalmic long-term effects of binimetinib 
treatment alone or in combination with RAF inhibitors in advanced melanoma. Binimetinib 
induces a dose-dependent retinopathy in almost 100% of the patients. The morphological 
aspects of this retinopathy including bilateral neuroretinal detachments with daily fluctuations 
and oedema of the outer retinal layers are highly specific for the treatment with MEK 
inhibitors. Especially patients undergoing monotreatment tend to develop bullous lesions 
which more frequently induce visual disturbances. The addition of the selective BRAF 
inhibitor encorafenib modulates the aspect of the retinopathy to flat and more extended 
detachments. None of the patients experienced persistent functional deficits even after a 
treatment duration of up to two years. The use of OCT for diagnosis and follow-up is 
mandatory; fundoscopy detected 70% of the lesions only. After initial thickness increase the 
retinal measurements gradually decreased and reached values even below screening after six 
months. After treatment stop there seems to be a partial recovery of retinal values. At present, 
the clinical significance of this retinal thinning is not clear and has to be addressed in future 
research. 
MEK inhibitor-induced retinopathy occurs in response to treatment with various types of 
MEK inhibitors and is therefore considered to be a class effect [15, 17, 18]. The MEK1/2 
inhibitors, which have already been evaluated in clinical trials, show considerable differences 
in their pharmacokinetics. The Tmax of binimetinib is about 1.18 hours and plasma half-life 8 
hours. The corresponding half-lifes for cobimetinib and trametinib are approximately 2 days 
(49 hours) and 4.5 days (108 hours), respectively [4]. These characteristics might highly 
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influence the incidence of adverse events, including retinopathy (the detection is dependent on 
the time point of examination).  
The term MEKAR is proposed in analogy to CAR, cancer associated retinopathy or MAR, 
melanoma associated retinopathy, both rare eye conditions with severe functional deficits 
observed in metastatic disease [23, 24]. Auto-immunologic based cross reactions between 
tumour antigens and retinal tissues were described. In MEK inhibitor treated patients a 
dysfunction of the highly active metabolism and fluid regulation of the retinal pigment 
epithelium (RPE), which is essential to supply the receptors, has been suggested as underlying 
aetiology [25]. This is supported by recent findings on functional deficits in investigations 
with electrophysiological methods [17]. Our findings confirm that the pathology is initiated at 
the outer retinal layers. In our observations, the first subtle changes in response to drug 
exposure were segmentation errors and oedema at the location of the RPE, followed by the 
interdigitation zone, which is attributed to the interdigitations of the apical processes of the 
RPE with the cone outer segments [26]. The appearance of the lesions is less pronounced after 
a few weeks of treatment, but still a time-dependent retinal response is observed. Taken into 
account that we observed a retinopathy in almost 100% of the binimetinib-exposed patients, 
this is unlikely the course of an allergic phenomenon or autoimmune reaction, but highly 
suggests a toxic reaction in response to MEK inhibitor exposure.  
We found evidence of a reduction in retinal measurements to below baseline values and the 
maintenance of these lower values even after discontinuing the MEK inhibitor. At present, the 
underlying cause of this finding remains unclear. Findings on the progression of  heredo-
degenerative retinal disease, in particular age-related macular degeneration, or toxic 
retinopathy have shown that the functional capacity of a stressed pigment epithelium – and 
hence the receptors – remains intact for a limited time and is followed by atrophy [27-29]. 
Similarly a stress reaction and disturbance of homoeostasis in the skin and finally chronic 
changes have been shown [14]. Our findings suggest partial resolution of the retinal thinning 
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after end of treatment. However, persistent degeneration in most retinal diseases is a slow 
developing process and our observation period of two years is most likely too short.  
With regard to patients with pre-existing eye disease, the exclusion of patients with a history 
of retinal vein occlusion from treatment with MEK inhibitors is probably not justified, as the 
pathogenesis of the condition that we describe is clearly different and involves a different 
retinal compartment. Venous occlusion and macular oedema occur in the inner retinal layers 
due to the dysfunction of the retinal vessels forming the inner blood-retinal barrier, while the 
pigment epithelium maintains the blood-retinal barrier to the choroid [30]. Classic central 
serous chorioretinopathy is thought to be primarily due to pathological changes in the choroid 
circulation, associated with a marked measurable thickening, and to hormonal influences [16]. 
Altogether, we demonstrate that a treatment with binimetinib is safe with regard to ocular 
adverse effects for a treatment duration of up to two years. Due to the fact that appearance of 
the retinal lesions is highly dose- and time-dependent, the time point of examination has 
strong diagnostic implications. In fundoscopy, about one third of the retinopathies are not 
detected, optical coherence tomography is therefore mandatory for a thorough monitoring of 
patients treated with all types of MEK inhibitors.  
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Figure legends 
Figure 1: Different aspects of binimetinib induced retinopathy in dependence of treatment. 
(A) left: binimetinib monotreatment 30mg BID: scanning laser ophthalmoscopy (SLO 
multicolour wide angle image) of the right eye demonstrates multiple bullous lesions 
distributed on the posterior pole; right: typical neuroretinal detachments on a horizontal line 
scan with optical coherence tomography (OCT) through the fovea (arrow). (B) Combined 
treatment with binimetinib 45mg BID and encorafenib 450mg QID, six months after 
treatment start: left: SLO image doesn’t reveal any particular pathology, right: on OCT a flat 
and wide spread neuroretinal detachment and oedema of the outer retinal layers were 
discovered (arrow). 
Figure 2. Course of retinal changes in patients during a time period of up to two years of 
treatment with binimetinib and RAF inhibitor (combination therapy) with regard to retinal 
volume (A), maximal (B) and minimal retinal thickness (C). The time difference to 
medication was d240min. Trend lines were smoothed using the 'stat_smooth' function of the 
ggplot2 package (method = 'loess') in R. Shading indicates 95% confidence intervals around 
the trend lines.  
Figure 3. Development of an exudative retinal lesion: At the screening examination (A) 
scanning laser ophthalmoscopy (SLO) (left) and a high resolution horizontal line optical 
coherence tomography (OCT) scan through the fovea (right) demonstrates normal 
morphology, with three strongly reflective bands of the outer retina. (B) day 14 after 
treatment start with binimetinib BID 45mg and encorafenib QD 450mg, 9.5 hours after last 
medication: On the left in the SLO and on the right on the OCT scan a foveolar lesion was 
detectable with an enormous oedema of the outer retinal layers, mainly of the interdigitation 
zone (yellow arrow, measurement: 52µm). On the same day 90 minutes after the morning 
dose of the tablets (C) a bilateral subfoval neuroretinal detachment with serous exudation had 
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developped, also visible on ophthalmoscopy. (D) Two weeks later 110 minutes after 
medication, SLO (left) was almost unremarkable, on the OCT scan (right) now four strongly 
reflective bands were present, still as a sign of oedema of the outer retina. On later visits these 
daily fluctuations were still present, mostly not more as some 15µm. 
Figure 4: Treatment-duration dependent changes of retinal volume (A), of maximal (B) and 
of minimal retinal thickness (C) in patients after intake of binimetinib (monotherapy or 
combined treatment). Retinal volume was measured in a 6mm circle diameter. Trend lines 
were smoothed using the 'stat_smooth' function of the ggplot2 package (method = 'loess') in 
R.  
Figure 5: Resolvement of binimetinib-induced retinopathy in a patient with pre-existing 
retinal diseases. (A) Drusen maculopathy: left: SLO multicolour image: multiple bullous 
lesions, the perifoveal smaller yellow spots respresent drusen; right: a horizontal line scan 
demonstrates oedema of the outer retinal layers and subfoveal exudation, the multiple 
irregular elevations below the retinal pigment epithelium represent the drusen. (B) Drusen 
maculopathy: Eight days after end of treatment: retinal contours returned to baseline, the 
drusen were unchanged (arrow). (C) Severe epiretinal gliosis: left: SLO image showed many 
lesions of different size and irregular reflections from the retinal surface; right: on a horizontal 
line scan an enormous elevation of the central retina with oedema of all layers and 
neuroretinal detachments at several positions (arrows) were detected. (D) Severe epiretinal 
gliosis: after a treatment stop: the lesions almost disappeared. 
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Tables 
Table 1. Baseline characteristics and incidence of retinopathy 
  All patients 
(n=62) 
Binimetinib 
monotherapy 
(n=13) 
BRAF 
inhibitor 
monotherapy 
(n=10) 
Combination 
therapy 
(n=39) 
Male sex 39 (63%) 9 (69%) 6 (60%) 24 (62%) 
Age (years) 55 (46-64) 61 (55-67) 57 (51-64) 53 (45-63) 
Length of observation (days) 170 (115- 
280) 
229 (78-314) 236 (168-324) 162 (116-263) 
NRAS mutated melanoma 13 (21%) 12 (92%) - 1 (3%) 
End of treatment 37 (60%) 9 (69%) 10 (100%) 18 (46%) 
RAF Inhibitor     
LGX818 (encorafenib) 43 (69%) 0 8 (80%) 35 (90%) 
RAF265 4 (6%) 0 0 4 (10%) 
Zelboraf  (vemurafenib) 2 (3%) 0 2 (20%) 0 
Number of OCT images 1233 277 (23%) 90 (7%) 866 (70%) 
Symptoms present 34 (55%) 5 (38%) 2 (20%) 27 (69%) 
Positive fundoscopy 37 (60%) 10 (77%) 0 27 (69%) 
Positive OCT 51 (82%) 12 (92%) 0 39 (100%) 
OCT morphology     
Bullae 29 (47%) 9 (69%) 0 20 (51%) 
Cleft 33 (53%) 2 (15%) 0 31 (79%) 
Oedema 51 (82%) 12 (92%) 0 39 (100%) 
Data are n (%) or median (IQR). OCT=Optical coherence tomography. 
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Table 2. Mixed model analysis on changes of retinal volume in response to binimetinib 
therapy.  
 
 Estimate (CI-95%) Significance 
Binimetinib dose, mg 0.0075 (0.0043, 0.0108) p<0.001 
RAF inhibitor -0.0043 (-0.2310, 0.2224) p=0.976 
Treatment duration, d -0.0003 (-0.0005, -0.0002) p=0.001 
Time elapsed since medication, min -0.0004 (-0.0004, -0.0003) p<0.001 
The table shows estimates and corresponding 95% confidence intervals. Patients before begin of treatment with 
binimetinib, without RAF inhibitor therapy and before intake of medication have been defined as the reference 
group in the mixed model. RAF inhibitor treatment was defined as treatment with either encorafenib, RAF265, 
or vemurafenib. We controlled for subject using a random intercept. Dependent variable: retinal volume (mm3).  
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Table 3. Mixed model analysis on changes of maximal retinal thickness in response to 
binimetinib therapy.  
 Estimate (CI-95%) Significance 
Binimetinib dose, mg 0.75 (0.55, 0.93) p<0.001 
RAF inhibitor -11.47 (-22.34, -0.60) p=0.091 
Treatment duration, d  -0.03 (-0.04, -0.02) p<0.001 
Time elapsed since medication, min -0.01 (-0.02, -0.01) p<0.001 
The table shows estimates and corresponding 95% confidence intervals. Patients before begin of treatment with 
binimetinib, without RAF inhibitor therapy and before intake of medication have been defined as the reference 
group in the mixed model. RAF inhibitor treatment was defined as treatment with either encorafenib, RAF265, 
or vemurafenib. We controlled for subject using a random intercept. Dependent variable: maximal retinal 
thickness (µm).  
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Table 4. Mixed model analysis on changes of minimal retinal thickness in response to 
binimetinib therapy.  
 Estimate (CI-95%) Significance 
Binimetinib dose, mg 0.68 (0.45, 0.91) p<0.001 
RAF inhibitor -4.23 (-18.80, 10.38) p=0.638 
Treatment duration, d -0.03 (-0.05, -0.02) p<0.001 
Time elapsed since medication, min -0.01 (-0.02, -0.01) p<0.001 
The table shows estimates and corresponding 95% confidence intervals. Patients before begin of treatment with 
binimetinib, without RAF inhibitor therapy and before intake of medication have been defined as the reference 
group in the mixed model. RAF inhibitor treatment was defined as treatment with either encorafenib, RAF265, 
or vemurafenib. We controlled for subject using a random intercept. Dependent variable: minimal retinal 
thickness (µm). 
 
